29 May 2020 | US | Alexion, Amgen | In a filing to the Securities and Exchange Commission, Alexion announces it has settled its eculizumab dispute with Amgen. Under the agreement, Amgen will receive a non-exclusive, royalty-free license to market its product from 01 Ma...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags